[Clinical experience with cefadroxil dry syrup in pediatric infections (author's transl)].
Cefadroxil was administered to 16 pediatric patients at dose levels ranging from 27 to 56 mg/kg daily for 5-9 consecutive days. Of 16 patients, 9 had urinary tract infections including 5 cases with nephrotic syndromes, 4 had respiratory tract infections including 2 cases with nephrotic syndromes, 3 had skin infections including 2 cases of pyoderma and 1 case of suppurative gingivitis, including 1 case with nephrotic syndrome. Clinical results obtained were 9 'excellent', 4 'effective' and 3 'ineffective' showing an efficacy ratio of 81%. Of 9 urinary tract infections, 5 patients exhibited bacteriuria and 3 had original pathogens persisting after treatment. In respiratory tract, skin and gingival infections, cefadroxil was either 'excellent' or 'effective' in all 7 patients. The above results demonstrate a distinctive feature of cefadroxil that attains a good cutaneous distribution after oral administration. The absorption of the drug was not adversely affected by a food intake. No significant side effects were observed in all 16 patients. Judging from our clinical results, cefadroxil is considered one of the valuable cephalosporin antibiotics in the treatment of pediatric infections.
D002434:Cefadroxil; D002506:Cephalexin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D004304:Dosage Forms; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004304:Dosage Forms; D002434:Cefadroxil; D002506:Cephalexin